Crosstalk between iron metabolism dysregulation and the oral microbiome in periodontitis Authors: Zhenyuan Yu, Shuwei Zhang, Ze Lu, Hongyan Wang, Haijie Liu, Yuchao Li, Yaping Pan Published: 2026 ABSTRACT AbstractBackgroundPeriodontitis is a chronic inflammatory disease caused by periodontal pathogens. The impact of periodontitis is not only limited to the oral cavity, but also related to a variety of systemic diseases. Iron is a kind of redox metal, which may be deleterious to cells by producing damaging free radicals. Iron homeostasis dysregulation, especially ferroptosis, involves in the progression of periodontitis.ObjectiveThis review aims to systematically summarize the crosstalk between iron metabolism dysregulation and the oral microbiome in periodontitis, focusing on alterations in iron-related biomarkers, iron-mediated tissue damage, the role of ferroptosis, and the potential of iron-targeted therapies.DesignA narrative review of recent advances in iron metabolism and ferroptosis, with emphasis on studies investigating molecular mechanisms, clinical correlations, and therapeutic interventions in periodontitis.ResultsIn periodontitis, serum iron and transferrin levels are decreased, while ferritin, hepcidin, and ceruloplasmin are elevated. Dysregulated iron metabolism promotes periodontal pathogen survival, amplifies inflammatory responses, induces ferroptosis in periodontal ligament cells, and contributes to alveolar bone resorption. Iron disorders also link periodontitis to systemic diseases such as anemia of inflammation, type 2 diabetes, and cardiovascular disease. Preclinical studies show that iron chelators (e.g. deferoxamine) and lactoferrin can inhibit bacterial growth, alleviate ferroptosis, and promote periodontal regeneration.ConclusionsIron metabolism dysregulation and ferroptosis play critical roles in the initiation and progression of periodontitis and its systemic comorbidities. Targeting iron homeostasis represents a promising therapeutic strategy, but further well-designed clinical trials are needed to validate efficacy and safety. Introduction Periodontitis is a chronic inflammatory disease and a global public health problem. Periodontal pathogens cause inflammatory and immune responses, leading to irreversible destruction of periodontal tissue, which is the main cause of tooth loss in adults [1]. In addition, periodontitis is also closely associated with systemic diseases such as diabetes and inflammatory anemia [2]. Iron is essential for human health and is tightly regulated in tissues and cells [3]. Iron deficiency in humans can lead to anemia, while excess iron has toxic effects on the body. Iron has redox ability and excess intracellular Fe2+ catalyzes the production of large amounts of reactive oxygen species (ROS) through the Fenton reaction, leading to lipid peroxidation and cell damage [4]. In recent years, the regulatory network of iron metabolism has been steadily exposed, and increasing evidence suggests that iron metabolism is disrupted in periodontitis. Clinical studies have found that serum iron levels are reduced in patients with periodontitis. The decrease in iron levels is related to the degree of periodontal inflammation and alveolar bone loss [5]. However, the specific mechanisms by which inflammatory mediators and bacteria disrupt iron metabolism in periodontitis remain unclear and require further elucidation. On the other hand, the disorder of iron metabolism in patients with periodontitis may aggravate local periodontal tissue damage. Moreover, lipid peroxidation induced by intracellular iron accumulation, accompanied by glutathione (GSH) depletion and glutathione peroxidase 4 (GPX4) inactivation, can lead to ferroptosis. Ferroptosis has recently been reported as a novel pathogenic mechanism in periodontitis. Furthermore, new research has discovered that iron acts as a ‘bridge’ between periodontitis and the development of systemic diseases, with the effects of iron homeostasis disorders in periodontitis even spreading throughout the whole body. Studies have attempted to alleviate periodontitis by removing excess iron, and iron chelating drugs have achieved some success in inhibiting the growth of periodontal pathogens and promoting periodontal regeneration. In this review, we will discuss recent advances in iron uptake, storage and excretion in the context of periodontitis, highlight the significance of iron disorders in patients with periodontitis, and summarize novel iron modulators under development that may offer new options for the treatment of periodontitis. Iron metabolism homeostasis Normal iron metabolism includes the stages of iron absorption, storage and excretion. Iron can be taken up by cells in a variety of ways, and TfR1 is the major iron uptake mechanism in many cells. The main mechanism is that transferrin (Tf) carries iron ions and binds to transferrin receptor 1 (TfR1) on the cell membrane to form a complex, which can be internalized into the cell and release Fe3+ [6]. Fe3+ is reduced to Fe2+ by the metal reductase, six-transmembrane epithelial antigen of prostate 3 (STEAP3), which is then transported into the cytoplasm by divalent metal transporter 1 (DMT1) [7]. Part of the iron that enters the cell is stored in the cytoplasm's labile iron pool (LIP) and then used to synthesize iron-containing protein in the mitochondria [8]. Another part of the iron in the cell is stored in ferritin, which is composed of a ferritin light chain (FTL) and ferritin heavy chain (FTH) in a shell-like structure, and its inner cavity can accommodate iron ions [9]. Excess Fe2+ is excreted from the cell via ferroportin (FPN), the only known iron-exporting protein. The released Fe2+ is rapidly oxidized to the Fe3+ form by ferroxidase, ceruloplasmin (Cp). Iron balance is very important for the human body. Iron homeostasis is regulated by IRE/IRP system and hepcidin. Regulation of the IRE/IRP system has not been reported in periodontitis, but it has been shown that hepcidin is abnormally expressed in periodontitis. Hepcidin mainly controls FPN through two known mechanisms: hepcidin blocks the open-outward conformation of FPN [10], and hepcidin induces FPN degradation [11], which in turn regulates iron homeostasis (Figure 1). Iron metabolism at the cellular level. The iron ion-binding Tf binds to TfR1 to form the Tf–Fe3+–TfR1 complex, which is internalized into the cell. Fe3+ entering the cell is reduced to Fe2+ via STEAP3 and then transported to the cytoplasm via DMT1. Some of the iron ions in the cells enter the LIP for the synthesis of heme, Fe–S cluster and other proteins in the mitochondria, while the other part is stored in ferritin. Excess iron ions in the cell are excreted from the cell by FPN. Hepcidin controls iron efflux from cells by regulating FPN. Fe2+ is oxidized to the Fe3+ form by ceruloplasmin. Disorders of iron metabolism homeostasis are associated with a variety of cellular states, including iron-driven oxidative stress, inflammasome activation and ferroptosis, which together contribute to chronic inflammation and tissue damage. Among them, ferroptosis is very important. Ferroptosis is an important among these processes. Ferroptosis, a new form of programmed cell death discovered in recent years, is characterized by iron-dependent lipid peroxidation and is closely related to iron metabolism disorders. In addition to iron metabolism, abnormal lipid metabolism and glutathione metabolism also induce ferroptosis. In addition, there are two monitoring mechanisms that inhibit ferroptosis. One is mediated by ferroptosis inhibitor protein 1 (FSP1), which is recruited to the plasma membrane, where it, by reducing coenzyme Q10, prevents the propagation of lipid peroxides [12,13]. The other is the phospholipase-modifying enzymes MBOAT1 and MBOAT2 as ferroptosis inhibitors. MBOAT1/2 inhibits ferroptosis by remodeling the cellular phospholipid profile [14] (Figure 2). In recent years, an increasing number of studies have focused on the role of ferroptosis in periodontitis. Therefore, we will also summarize the relationship between ferroptosis and periodontitis. Metabolic pathways involved in ferroptosis. Many aspects of iron metabolism, such as iron absorption, storage and utilization, play an important role in regulating ferroptosis. The activation of long-chain fatty-acid CoA ligase 4 (LACS4), lipoxygenase (LOX) and other enzymes in the lipid metabolism pathway promote lipid peroxidation and ferroptosis. The classical ferroptosis inhibition pathway is mediated by glutathione peroxidase 4 (GPX4). Glutathione (GSH) acts as a cofactor of GPX4, and both reduce phospholipid hydroperoxides to their corresponding alcohols. Phospholipid peroxidation is also regulated by ferroptosis inhibitor 1 (FSP1) and MBOAT1/2. PUFA, polyunsaturated fatty acid; PUFA–CoA, coenzyme A-activated polyunsaturated fatty acid; PUFA–PL, polyunsaturated fatty acid-containing phospholipid; LPLAT5, lysophospholipid acyltransferase 5; GSSG, glutathione disulfide. Dysregulated iron metabolism in periodontitis Iron metabolism and bacterial infection share a complex relationship, as iron serves not only as an essential trace element for humans but also as a requirement for the growth and reproduction of most bacteria. Bacteria typically rely on iron to sustain their metabolic activities, particularly in oxidative phosphorylation, DNA synthesis and enzyme function. When bacteria infect host cells and tissues, a key defensive manner of the host against infection is to restrict bacterial access to iron, leading to elevated iron concentrations within cells. Periodontitis is a chronic inflammatory disease driven by periodontal pathogens, resulting in altered iron metabolism (Table 1). High-throughput omics technologies have revealed that signaling pathways associated with iron homeostasis are activated in periodontitis [15,16]. Concurrently, clinical studies have identified changes in certain iron metabolism markers among periodontitis patients [17,18]. Changes in iron metabolism in the context of periodontitis in terms of three phases: iron transport, iron storage and iron excretion (Figure 3). Table 1.The altered iron metabolism markers in periodontitis.Iron metabolism markersHealthy groupPeriodontitis group p-valuesReferencesSerum iron16.55 ± 5.43 μmol/L13.16 ± 4.54 μmol/L0.002[19]104.60 ± 31.80 μg/dL88.80 ± 38.00 μg/dL0.500[20]16.54 ± 5.09 μmol/L14.58 ± 3.22 μmol/L0.037[21]100.80 ± 6.70 mcg/dL71.40 ± 5.10 mcg/dL<0.010[22]Transferrin (mg/dL)290.50 ± 54.97252.20 ± 54.47<0.001[19]290.60 ± 53.46252.90 ± 52.50<0.001[21]307.80 ± 11.70213.10 ± 9.20<0.001[23]Ferritin (ng/mL)105.30 ± 81.16153.80 ± 106.500.044[19]127.10 ± 127.60125.20 ± 130.600.290[20]96.65 ± 75.57176.70 ± 110.00<0.001[21]196.20265.100.008[24]67.82 ± 6.5799.740 ± 4.23<0.001[25]Hepcidin(ng/mL)20.65 ± 16.4238.91 ± 25.48<0.001[19]28.38 ± 18.1943.35 ± 29.400.004[21]60.90 ± 13.0065.60 ± 14.300.090[20]179.37 ± 79.86249.56 ± 77.150.003[24] The altered iron metabolism markers in periodontitis. Altered iron metabolism in periodontitis. Inflammation occurs after bacterial infection of periodontal tissues, and the pro-inflammatory cytokines IL-6 and TNF-α promote increased ferritin expression. At the same time, IL-6 promotes increased hepcidin synthesis via the JAK/STAT3 pathway. Hepcidin inhibits FPN, which ultimately leads to an increase in intracellular iron. Alterations of iron metabolism-related biomarkers in periodontitis Transferrin receptor, a membrane-bound glycoprotein, is a marker of cell proliferative activity [26]. Periodontitis is characterized by the loss of junctional epithelial attachment and apical migration of the epithelium, and it has been found that periodontal bacteria stimulate increased expression of TfR1 in junctional epithelial cells at the bottom of the periodontal pocket [27]. This indicates that transferrin receptors can be expressed in response to external stimuli. However, bacteria also reduce TfR1 levels. This occurs because periodontal bacteria secrete gingipain or gingipain-containing outer membrane vesicles during tissue invasion [28], which degrade host cell surface proteins. These enzymes detach and hydrolyze membrane proteins, including TfR1, converting them into nutrients for bacterial survival [29]. Notably, the reported upregulation and degradation of TfR1 appear paradoxical. This discrepancy may be attributable to differences in experimental conditions, such as acute versus chronic infection models or variations in bacterial virulence factors. Bacteria-induced TfR1 expression in the junctional epithelium suggests a compensatory mechanism for iron uptake; however, the limitations of these studies restrict the generalizability of their findings to systemic iron status. Salivary transferrin is sensitive to chronic inflammation, and decreased salivary transferrin expression has been reported in certain chronic inflammatory diseases, such as oral lichen planus and psoriasis [30,31]. Clinical studies indicate that the mean serum transferrin levels in patients with periodontitis are significantly lower than those in the healthy population [23,32]. Following three months of periodontal basic treatment, the serum transferrin levels approached normal levels [23]. A substantial proportion of patients with periodontitis have a history of smoking. A cross-sectional study has shown that smokers exhibit lower levels of transferrin and VEGF in saliva [33]. This indicates that smoking is also a significant risk factor contributing to reduced transferrin levels in periodontitis. Additionally, periodontal pathogens represent another cause of transferrin reduction. Their growth and reproduction require iron, and transferrin serves as a crucial iron source for these bacteria. Periodontitis patients exhibit detectable levels of transferrin fragments in gingival crevicular fluid, resulting from the degradation of transferrin by periodontal pathogens to obtain iron [34]. Ferritin, the major iron storage protein in cells, consists of FTL and FTH and is an important component of the regulatory network for maintaining iron homeostasis. Clinically, the serum ferritin level is an important indicator for assessing iron reserves, and a cross-sectional study demonstrated that the serum ferritin level was significantly higher in patients with periodontitis compared with periodontally healthy individuals [19]. Serum ferritin levels were significantly and positively correlated with a probing depth (PD) ≥ 6 mm [25], and its levels significantly decreased after non-surgical periodontal treatment [35]. Notably, the level of ferritin expression is regulated by inflammatory signaling [36]. Pro-inflammatory cytokines regulate ferritin expression in distinct ways. Interleukin-6 (IL-6) promotes the expression of FTL [37], whereas tumor necrosis factor α (TNF-α), IL-1α, IL-1β and lipopolysaccharide (LPS) activates FTH expression [37–40]. When FTH and FTL expression is upregulated, they can resist oxidative damage by hydroxyl radicals and exert antioxidant effects during inflammation. This may be an early cell defense against bacterial and inflammatory stimuli. In periodontitis, Porphyromonas gingivalis-LPS (P. gingivalis-LPS), IL-6 and TNF-α can also exacerbate ferritin expression in periodontal ligament cells (PDLCs) [41]. During periodontitis, serum FPN levels are downregulated, thereby limiting cellular iron export and promoting intracellular iron retention [19]. This inflammation-driven suppression of FPN is largely thought to result from the activation of host immune responses [42]. Mechanistically, inflammatory signaling exerts transcriptional repression of FPN expression, with mediators such as LPS [43] and IL-6 [37] demonstrated to downregulate FPN mRNA expression. In addition to its direct suppressive effect on FPN, IL-6 is a key upstream regulator of hepcidin levels [44,45]. Clinical studies have consistently demonstrated elevated IL-6 levels in both the saliva and serum of patients with periodontitis [46]. It was found that serum hepcidin levels were significantly and positively correlated with circulating IL-6 levels [19,47]. Moreover, periodontal therapy leads to concomitant reductions in hepcidin, IL-6 and C-reactive protein levels, further supporting the role of the IL-6-hepcidin axis in inflammation-associated iron dysregulation during periodontitis [20]. CP is not only an oxidase but also an acute-phase reactant that is increased under inflammatory conditions. It has been demonstrated that CP levels are increased in periodontitis patients compared to the healthy [48,49], and it is positively associated with increased clinical attachment loss (CAL) [49]. CP catalyzes the conversion of iron ions from ferrous ions to ferric ions, thereby facilitating more ferric ions internalized into the cells. Notably, although most clinical studies have reported significantly elevated levels of serum iron, ferritin and hepcidin in periodontitis, inconsistencies have been observed. For instance, Leite et al. found no significant differences between healthy and periodontitis groups [20]. This inconsistency may be associated with the relatively small sample size, which potentially reduced the statistical power. Furthermore, the periodontitis group in their cohort exhibited relatively low mean PD and CAL levels, suggesting limited periodontal destruction. This relatively mild disease severity may have reduced the ability to detect changes in these biomarkers. Nevertheless, despite baseline variability, these indicators tend to normalize following initial periodontal therapy, further underscoring their potential as markers of therapeutic response. Diagnostic, prognostic and monitoring value of iron metabolism-related biomarkers in periodontitis Growing evidence supports a link between iron dyshomeostasis and the pathogenesis of periodontitis, indicating the potential utility of iron-related biomarkers in disease diagnosis, prognostic assessment and longitudinal monitoring. However, existing findings exhibit considerable heterogeneity, necessitating a cautious evaluation of their clinical applicability. As summarized in Table 1, increased serum ferritin and hepcidin levels in periodontitis support their potential as auxiliary diagnostic biomarkers. Nevertheless, given their elevation in other inflammatory conditions, their specificity may be limited and should be interpreted alongside clinical parameters such as PD and CAL. Regarding prognosis, elevated transferrin saturation (TSAT > 45%) has been identified as a potential risk indicator for rapid periodontal progression, with affected individuals exhibiting an approximately twofold increased risk of severe attachment loss [50,51]. Similarly, the positive correlation between serum ferritin and PD ≥ 6 mm underscores its relevance in reflecting disease severity and the extent of alveolar bone resorption [25]. Nonetheless, current evidence supporting its prognostic utility remains largely indirect and is derived primarily from cross-sectional studies. There is a lack of longitudinal clinical studies evaluating whether baseline iron metabolism indices can reliably predict disease progression or therapeutic outcomes. Iron metabolism-related biomarkers may also serve as indicators of disease activity and treatment response. For example, serum transferrin levels tend to normalize within three months following periodontal therapy. Furthermore, the synchronized decline in hepcidin and IL-6 post-treatment reflects the resolution of local infection and systemic inflammation, suggesting their potential utility as biological indicators of therapeutic response [20]. However, evidence in this area remains limited, and standardized approaches for dynamic monitoring are currently lacking. It remains unclear whether changes in these markers offer sufficient sensitivity and specificity to capture disease dynamics. Moreover, confounding factors, including systemic health and iron nutritional levels, complicate clinical interpretation. Consequently, future research should prioritize well-designed prospective and longitudinal clinical studies. Emphasis should be placed on developing multi-marker panel approaches that integrate iron metabolism indices with inflammatory cytokines and microbial profiles. Furthermore, developing detection methods based on localized samples (e.g. gingival crevicular fluid, GCF) and establishing standardized cutoff values for iron-related markers in saliva or GCF will be crucial. Implementing point-of-care testing for disease monitoring and prognostic assessment may further enhance the clinical utility of these biomarkers in periodontal management. Iron metabolism disorders promote the development of periodontitis and systemic diseases Iron contribute to the survival of periodontal pathogens Iron is indispensable for bacterial survival and pathogenicity. Extracellular bacteria have employed various strategies to acquire non-free iron, while intracellular bacteria obtain iron directly from within the cell. Since free iron is toxic to human tissues, most of the iron in human blood exists in the form of iron-binding proteins such as transferrin and lactoferrin. This has resulted in an extremely low amount of free iron available for bacterial acquisition. Consequently, bacteria have evolved diverse strategies to overcome host-imposed iron restriction. In periodontitis, Acinetobacter baumannii [52] is able to produce iron carriers that compete with transferrin and lactoferrin, among others, for bound iron. Other pathogens (e.g. Campylobacter rectus [53], Treponema denticola (T. denticola) [54]) can also secrete ferric reductase, which reduces Fe3+ to the more soluble Fe2+ form for utilization. Nevertheless, some periodontal bacteria (e.g. P. gingivalis [55], Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans) [56]) can bind and cleave compounds such as heme, hemoglobin and transferrin to obtain iron. During the progression of periodontitis, hemoglobin concentration may increase due to the leakage of hemoglobin from damaged blood vessels in the gingiva. P. gingivalis encodes the gingival proteases RgpA and Kgp, which degrade hemoglobin to release heme. Subsequently, P. gingivalis secretes the outer membrane proteins HmuY and HmuR to capture and transform heme to obtain iron [55]. Beyond a single iron-acquisition strategy, periodontitis progression involves complex synergistic interactions within the oral microbiome. Although P. gingivalis utilizes its gingipains to liberate heme or iron from host hemoglobin, the released iron may function as a public resource, supporting the growth of other subgingival bacteria that lack potent proteolytic capacity [57]. In addition, metabolic cooperation and spatial organization within the biofilm facilitate resource sharing and functional complementarity, thereby enabling the entire microbial community to adapt better to iron-restricted environments. These synergistic interactions may enhance the pathogenicity and persistence of the microbial consortium [58]. This altered iron utilization contributes to microbial dysbiosis, driving the transition from a health-associated microbiota to a pathogenic microbial community, ultimately promoting the progression of periodontitis. Concurrently, elevated intracellular iron levels resulting from iron dyshomeostasis facilitate bacterial iron acquisition, thereby exacerbating intracellular infections. Studies on various intracellular pathogens, such as Mycobacterium tuberculosis and uropathogenic Escherichia coli, have confirmed that these bacteria exploit host iron stores to promote lipid peroxidation, ultimately leading to ferroptosis [59,60]. Multiple studies indicate that bacteria within periodontal pockets can invade gingival tissues, causing persistent infections, including A. actinomycetemcomitans, Tannerella forsythia, T. denticola, Fusobacterium nucleatum (F. nucleatum) and P. gingivalis [61]. Periodontal pathogens primarily enter cells via endocytosis. For example, P. gingivalis escapes immune clearance by inducing complement receptor 3 (CR3) to internalize into macrophages. Macrophages also serve as the primary storage cells for circulating iron, being rich in iron content. Consequently, P. gingivalis readily accesses the iron stored within macrophages [62], thereby enhancing its intracellular survival, promoting virulence factors release, and amplifying the production of inflammatory mediators. Similarly, F. nucleatum and A. actinomycetemcomitans have been demonstrated to activate ferroptosis by invading cells and disrupting iron metabolism [63,64], further underscoring the relevance of this mechanism in the pathogenesis of periodontitis. This suggests that during periodontitis, an imbalance in iron metabolism—specifically increased intracellular iron concentrations—may confer advantages to pathogens invading periodontal tissues. Iron metabolism disorders amplify immune and inflammatory responses in periodontitis Under persistent periodontal infection, the host's iron metabolism regulatory mechanisms often become disrupted, leading to iron homeostasis imbalance. This metabolic abnormality not only alters the local redox state but also may further amplify the immune response to periodontitis by affecting immune cell function and inflammatory signaling pathways, thereby creating favorable conditions for continued disease progression. Iron, a key regulator of immune function and redox balance, accumulates progressively in periodontal cells under chronic inflammatory conditions. This directly affects the activation of inflammatory signals, mainly free iron, which promotes inflammation through the generation of reactive oxygen species. Ferritin autophagy occurs when NCOA4 in periodontal ligament cells mediates ferritin to lysosomes after P. gingivalis stimulation [65]. This leads to increased free iron concentration and ROS production in cells, which promotes increased production of pro-inflammatory cytokines (TNF-α, IL-6 and IL-1β). In addition to storing iron, ferritin is an acute-phase protein with immunomodulatory functions [66]. In infections and inflammation, ferritin is secreted extracellularly to promote inflammatory responses. P. gingivalis-LPS has been shown to be a factor in promoting ferritin secretion [41]. Extracellular ferritin is involved in the production of the pro-inflammatory cytokines IL-6 and IL-8 through the TfR1 and ERK/P38 MAPK pathways [41]. In addition, the serum transferrin saturation (TSAT) level is associated with periodontitis, TSAT > 45% is positively correlated with the severity of periodontitis. Some studies have shown that patients with TSAT > 45% were 1.93 times more likely to have rapid progression of periodontitis [50,51]. TSAT refers to the iron-binding capacity of Tf and is calculated by dividing the serum iron concentration by the total iron-binding capacity, which reflects the concentration of Tf in the serum. When TSAT is below 20%, it indicates iron deficiency in the plasma; when this indicator is greater than 45%, non-transferrin-bound iron (NTBI) is present in the plasma [67]. NTBI is a bioavailable form of iron. This iron may be more bioavailable to bacteria and can promote the dysbiosis of flora in subgingival tissues [68]. Moreover, NTBI is more conducive to the production of ROS through the Fenton reaction and the aggravation of inflammation [51]. Recently, the relationship between iron metabolism and immune regulation has received increasing attention [69]. FTH stimulates macrophages with a significant increase in the gene expression of IL-1β, IL-6, IL-12, TNF-α and NLRP3 [70]. NLPR3 is a cytoplasmic innate immune signaling receptor that is a major factor in IL-1β production and maturation [71]. At the same time, there is evidence that iron overload is closely associated with macrophage polarization [72]. Pro-inflammatory cytokines associated with NF-κB and TNF-α signaling pathways are significantly increased after bacterial infection in iron overload mice and further recruit neutrophils by triggering interleukin IL-1β signaling [73]. Recently, it has also been found that hepcidin promotes the production of CXCL1 chemokines by keratin-forming cells, leading to neutrophil recruitment [74]. Iron homeostasis affects not only innate immunity but also determines T cell-mediated immune responses. Iron upregulates T-cell immunoglobulin and mucin containing protein-3 (TIM-3) to regulate Th1 T-cell differentiation, thereby affecting the control of infection by intracellular pathogens [75]. In periodontitis, the mechanisms by which iron and iron metabolism-related molecules regulate the immune response remain to be elucidated. Despite accumulating evidence linking iron metabolism to immunoregulation, current studies largely focus on individual pathways and the integrated crosstalk among these pathways in periodontitis remains elusive. Iron metabolism disorders promote the damage of periodontal bone tissue Excessive iron deposition was found in the periodontal ligament, gingiva and alveolar bone in mice with hereditary hemochromatosis, an iron-loading disease. Iron overload resulted in alveolar bone resorption, increased distance from the cemento-enamel junction to the alveolar bone crest, and increased expression of the pro-inflammatory cytokine IL-6 in mice [76]. Excess iron in cells affects the metabolism of osteoblasts and osteoclasts. Excess iron inhibits the differentiation of MSCs into osteoblasts through the downregulation of Runx2 [77]. Runx2 is a key transcription factor for the differentiation of MSCs into osteoblasts. Iron overload can also elevate ROS levels in pro-osteoblasts and produce cytotoxic effects [78]. Additionally, iron overload induces apoptosis in pro-osteoblasts through a cystathionine-dependent mechanism [78]. And excess iron-induced oxidative stress stimulates osteoclast differentiation through the NF-κB signaling pathway, which causes bone loss. Recent studies have shown that hepcidin and iron metabolism are related to osteoporosis [79,80]. Guo et al. found that hepcidin increased the proliferation and differentiation of osteoclast precursors and caused trabecular bone loss by down-regulating FPN expression and increasing intracellular iron levels [80]. Another study similarly showed that hepcidin knockout aggravated bone loss in the hind limbs of mice, most likely because of the reduced osteoblast activity of hepcidin knockout by affecting the Wnt/β-catenin signaling pathway [81]. In an apical periodontitis study, it was found that the apical periodontitis rats had increased alveolar bone loss compared with the control rats. Meanwhile, the apical periodontitis rats showed hepcidin expression in the extracellular membrane of periapical lesions but not in the normal group, suggesting that hepcidin plays an important role in the progression of apical periodontitis and alveolar bone loss. Another bioinformatics analysis showed that hepcidin was the core gene of epithelial‒mesenchymal transition in the Hertwig epithelial root sheath, which is an important process in the growth of teeth and surrounding periodontal tissues [82]. Therefore, we can relate whether hepcidin promotes alveolar bone resorption in periodontitis. Is it a key target for periodontal tissue regeneration? These issues are worthy of further exploration. Ferritin is widely present in periodontal tissues and is especially highly expressed in periodontal ligament cells (PDLCs) [83]. Ferritin has been reported to be involved in the cell differentiation and mineralization of PDLCs, while both iron excess and iron deficiency have an impact on the cell osteogenic differentiation and function of PDLCs [84,85]. Studies have shown that high ferritin and TSAT levels are highly correlated with clinical attachment loss ≥4 mm. In addition to the destruction of periodontal tissue by inflammation, the regulatory effect of ferritin on PDLCs may also be a possible reason. Yuan et al. also found that IL-17A induced ferritin expression in osteoblasts and that knockdown of FTH significantly reduced Runx2 expression [86]. A recent study has revealed that monocyte-derived ferritin synergizes with RANKL to drive pathological osteoclastogenesis. This ferritin-RANKL interaction enhances the expression of osteoclast resorption-associated genes (MMP9, CTSK, TRAP). These mechanisms collectively explain the clinical correlation between elevated ferritin levels in gingival crevices and accelerated alveolar bone loss in periodontitis [87]. However, most of these findings are based on animal models or in vitro experiments, and clinical evidence directly linking iron metabolism to alveolar bone loss in periodontitis patients remains limited. Iron metabolism disorders induces ferroptosis in periodontitis Several studies have demonstrated that ferroptosis plays an important role in the development of periodontitis, as shown in Table 2. LPS from periodontal bacteria is the primary cause of ferroptosis in periodontal tissues. Under LPS-stimulated inflammatory conditions, ferroptosis is activated in hPDLSCs, leading to reduced Klotho expression. Further experiments confirmed that Klotho overexpression effectively suppresses ferroptosis in hPDLSCs and significantly maintains their osteogenic potential in in vitro inflammatory environments [88]. Butyrate is a short-chain fatty acid produced by the continuous growth and proliferation of periodontal anaerobic bacteria. Induced by butyrate, ferritin autophagy occurs in cells, which leads to a significant increase in free iron levels in cells and excessive ROS production by Fe2+ through the Fenton reaction. Long-term treatment with butyrate leads to excessive ROS accumulation, GSH depletion, decreased GPX4, and ultimately ferroptosis in periodontal ligament fibroblasts [89]. The mechanism by which butyrate induces ferroptosis is mainly that it promotes NCOA4-mediated ferritin phagocytosis by regulating HIF-1a/p38 pathway and bromodomain-containing protein 4 (BRD4)/cyclin-dependent kinase 9 (CDK9) interaction [89]. Another study found that NCOA4 was significantly upregulated in both in vitro and in vivo models of periodontitis, leading to ferritin degradation and iron overload. Post-treatment with Fer-1 effectively reduces oxidative stress and iron accumulation [90]. Long-stranded non-coding RNA (lncRNA) plays a crucial role in the development and progression of periodontitis. LINC00616 was found to be highly expressed in P. gingivalis-LPS-treated periodontal ligament stem cells (PDLSCs) with ferroptosis, and knockdown of LINC00616 promoted cell viability and inhibited ferroptosis in PDLSCs. LINC00616 was found to promote ferroptosis in PDLSCs, mainly through microRNA-370 and the transferrin receptor axis [91]. LPS-stimulated hPDLF cells exhibit reduced expression levels of lncRNA-KAT7 and GPX4. Overexpression of lncRNA-KAT7 suppresses LPS-induced cell death and ROS levels in human periodontal ligament fibroblasts (hPDLF) cells, while promoting the expression of the ferroptosis-related proteins GPX4, SLC7A11 and HO-1 [92]. The colonization of periodontal pathogens is a major cause of periodontitis, and subgingival plaque can induce a variety of host responses, including ferroptosis. A. actinomycetemcomitans of human gingival epithelial cells induced significant ROS accumulation, indicating its capacity to trigger oxidative stress and activate the ferroptosis pathway [64]. F. nucleatum has been found to activate ferroptosis by interfering with iron metabolism in PDLSCs [63], but the exact mechanism has yet to be further investigated (Figure 4). Table 2.The involvement of ferroptosis in the progression of periodontitis.Cell or animal typesInterventionsCharacteristics or changesSignaling pathwaysReferencesHGEC A. actinomycetemcomitans infectionSLC7A11, GPX4 and NFE2L2, was significantly reducedDownregulated the expression of CDH1 and CLDN1[64]PDLSC F. nucleatum infectionFe2+ elevation [63]PDLSC P. gingivalis LPSElevated expression of ROS, Fe2+ and MDALINC00616-microRNA370-transferrin receptor axis[91]PDLFButyrate inductionElevated expression of ROS, MDA and Fe2+; decreased expression of GSH, GPX4HIF-1a/p38 pathway and BRD4/CDK9 interaction promote NCOA4-mediated ferritin autophagy[89]PDLF P. gingivalis LPSMitochondrial contraction; increased mitochondrial membrane density; ROS, PTGS2, TfR1 and MDA expression upregulated; SLC7A11, GPX4, SOD and GSH expression downregulated [93]BMSC P. gingivalis-derived OMVsIron overload; PTGS2, MDA expression upregulatedHippo-YAP pathway[94]MurineLigature-induced periodontitis modelFerroptosis [95]HGEC: human gingival epithelial cells; PDLSC: periodontal ligament stem cells; PDLF: periodontal ligament fibroblasts; BMSC: bone marrow mesenchymal stem cells. The involvement of ferroptosis in the progression of periodontitis. HGEC: human gingival epithelial cells; PDLSC: periodontal ligament stem cells; PDLF: periodontal ligament fibroblasts; BMSC: bone marrow mesenchymal stem cells. Ferroptosis in periodontitis. In periodontitis, iron overload, decreased GSH and GPX4 expression, increased ROS in cells and reduced mitochondrial volume lead to ferroptosis. Effects of disorders of iron metabolism in periodontitis on systemic organs Periodontitis is not merely a chronic inflammatory disease confined to the oral cavity. Its associated iron metabolism disorder is increasingly recognized as a crucial pathological link connecting local lesions to systemic damage throughout the body. This disorder is widely implicated in the onset and progression of various systemic diseases, including inflammatory anemia [96], diabetes [97] and cardiovascular disease [98]. Furthermore, with the recent emergence of the concept of ferroptosis, researchers have discovered that this process not only contributes to the pathogenesis of periodontitis but also may serve as a key mediator driving systemic health deterioration. The local inflammation of periodontitis can have an impact on systemic health, and available evidence suggests that the severity of tissue damage following periodontitis is directly proportional to the amount of iron accumulation. Anemia of inflammation (AI), also known as chronic disease anemia, is usually associated with chronic inflammatory diseases [99]. Periodontitis is an inflammatory disease in which the host immune system fights bacterial infection, and several recent studies have reported that periodontitis is closely associated with AI [96,100,101]. In an analysis of a clinical study involving more than 800 patients, an association between periodontitis and reduced hemoglobin (HB), mean erythrocyte hemoglobin (MCH) concentration and hematocrit (HCT) levels was shown [100]. Patients with periodontitis have a propensity for AI. Disturbed iron metabolism is a major pathogenic factor in AI, and mouse models of periodontitis show reduced HGB, HCT, serum iron levels, elevated hepcidin and ferritin levels [19]. The increased expression of hepcidin and ferritin in periodontitis is part of the host's defense mechanism against infection. This allows more iron to enter the cells and less iron in the serum for erythropoiesis and eventually leads to anemia. Through metagenomic analysis, ferroptosis and abnormal iron metabolism pathways were significantly enriched in periodontitis-diabetic patients. One study showed that patients with both periodontitis and type 2 diabetes had a significantly lower hepcidin/ferritin ratio than patients with type 2 diabetes alone [24]. When this ratio decreases, it indicates that the hepcidin produced is not sufficient to meet the excess iron in the body, which leads to iron accumulation in tissues [102]. This result suggests that periodontitis may be the main cause of the exacerbation of hepcidin deficiency in patients with type 2 diabetes. Furthermore, excess iron and insufficient hepcidin production may promote type 2 diabetes [103]. Therefore, it has been speculated that periodontitis may contribute to the development of type 2 diabetes by inducing iron overload and insufficient hepcidin production. A recent study using bioinformatics analysis has shown that ferroptosis is a key target for the pathogenesis and treatment of periodontitis in type 2 diabetes [104]. While bioinformatic analyses have suggested that ferroptosis is a potential cross-talk pathway linking periodontitis and diabetes, future research should move beyond association studies toward interventional clinical trials. For cardiovascular diseases, iron deficiency exacerbates disease progression. Several randomized controlled trials have found that serum ferritin and TSAT levels are strongly linked with cardiovascular disease mortality and prognosis [105]. Chronic inflammation is an important cause of iron deficiency in patients with cardiovascular disease, and it has been shown that patients with both periodontitis and cardiovascular disease have higher serum hepcidin levels [106]. This suggests that periodontitis can aggravate the severity of the disease by affecting the disorder of iron metabolism. This also indicates that for patients with periodontitis, iron metabolism-related indicators may be biomarkers of systemic diseases such as AI, which is an important hint. However, current studies are limited. Atrial fibrillation is a common arrhythmia driven by chronic inflammation [107]. A multivariate regression analysis utilized the ferritin/hemoglobin ratio—an indicator reflecting chronic inflammation and impaired iron utilization—to determine the impact of periodontitis on elderly atrial fibrillation patients. Results demonstrated a positive correlation between periodontal pocket depth > 4 mm and the ferritin/hemoglobin ratio. This suggests that severe periodontitis may exacerbate the pathophysiological processes of atrial fibrillation through systemic inflammation and iron metabolism disorders [108]. Periodontitis can also promote the development of lung and liver diseases by inducing ferroptosis. Experimental models have shown that periodontitis can exacerbate COPD by upregulating ferroptosis, and this promoting effect is prolonged over time [109]. P. gingivalis enters the blood circulation and spreads throughout the body, increasing the risk of systemic diseases. After P. gingivalis reaches hepatocytes, it promotes intracellular lipid peroxidation and leads to ferroptosis, which is a promoting factor of alcoholic liver disease (ALD) and non-alcoholic fatty liver disease (NAFLD) in mice [110,111]. Research also indicates that F. nucleatum can migrate to the gastrointestinal tract via saliva or hematogenous pathways, exhibiting extensive ectopic proliferation in mice with ulcerative colitis (UC). It can induce ferroptosis in intestinal epithelial cells, thereby promoting the onset and progression of UC [112]. Alzheimer's disease is also accompanied by dysregulation of brain iron homeostasis. Obtaining iron from brain tissue by P. gingivalis after entering the brain can disrupt brain iron balance, and Liu et al. speculated that the poor iron distribution in AD may be due to the release of OMV by P. gingivalis to transfer iron from the blood stream to the brain (Figure 5). However, the associations between periodontitis and systemic diseases mediated by iron are predominantly derived from experimental data. The causal relationships remain to be established, necessitating further large-scale epidemiological investigations. The role of iron disorders in periodontitis. The potential of iron therapy in periodontal therapy Antibiotics are now widely used as a treatment for periodontitis, but antibiotic resistance has become a serious public health problem. New therapeutic agents that target bacterial growth and bacterial metabolism are being explored. Iron plays an important role in the growth and virulence of periodontal pathogenic bacteria, while disturbances in iron metabolism promote inflammation, alveolar bone resorption and ferroptosis in periodontitis. Therefore, iron-targeted therapy may be a promising approach in periodontal therapy. The role of small molecule compounds in periodontitis by chelating iron Periodontal pathogens need access to iron to maintain their survival in subgingival tissues. Some studies have found that tea polyphenols [113] and myricetin [114] from natural products have the ability to chelate iron and they can inhibit the growth of F. nucleatum and P. gingivalis by chelating iron. Recently, it has also been found that the growth of bacteria can be inhibited by Maillard reaction products (MRP), which are formed in the body from glucose and protein. Large amounts of MRP in the body are known as advanced glycosylation end products (AGEs) and have implications for aging, diabetes mellitus and cardiovascular disease [115]. However, in vitro studies have shown that MRP inhibits the growth of A. actinomycetemcomitans by chelating iron [116]. Some MRPs are also present in the oral cavity and may enter the gingival sulcus to inhibit periodontal pathogens. Bismuth drugs are often used along with antibiotics to eradicate H. pylori and prevent the recurrence of stomach infections. Cheng et al. found that bismuth compounds disrupt the ability of P. gingivalis to acquire iron and inhibit P. gingivalis in plankton, biofilms and internalized in gingival cells [117]. Additionally, it counteracts the immune inflammatory response of host cells. Periodontitis is often accompanied by the loss of alveolar bone. Iron overload can lead to bone loss by inhibiting the proliferation of osteoblasts and promoting the differentiation of osteoclasts [118]. The iron chelator-deferoxamine (DFO) promotes the osteogenic differentiation of human periodontal cells through the nuclear factor erythroid 2-related factor (Nrf2)-mediated antioxidant signaling pathway [119]. This suggests the potential of iron chelators to block alveolar bone resorption in periodontitis. Curcumin also has osteogenic effects, and scaling and root planning (SRP) + curcumin treatment of rats with periodontitis for 4 weeks showed a decrease in iron deposition along with a decrease in the number of osteoblasts [120]. Moreover, carnosic acid (CA) is a naturally occurring phenolic diterpene molecule with diverse biological functions, including antioxidant, anti-inflammatory and cytoprotective effects. Recent studies have indicated that CA significantly reduces ROS and MDA levels in periodontal tissues by activating the Nrf2/GPX4 signaling pathway, inhibits Fe²⁺ accumulation and upregulates the expression of GPX4, SLC7A11 and FTH1 [121]. Neobavaisoflavone (NBIF) is a natural flavonoid. Studies have demonstrated that NBIF significantly inhibits osteoclast differentiation, F-actin ring formation, and bone resorption. Its primary mechanism involves direct binding to Keap1, stabilizing Nrf2 and promoting its nuclear translocation. This upregulates the iron export protein FPN1, reduces intracellular iron levels and suppresses the ferroptosis signaling pathway and cellular senescence [122]. Iron chelators have been extensively investigated for their capacity to inhibit bacterial proliferation and mitigate oxidative damage by sequestering iron. Common agents, such as DFO, have demonstrated significant antimicrobial and anti-inflammatory effects in both in vitro studies and animal models. However, most evidence supporting iron chelation remains preclinical, and robust clinical data in patients with periodontitis are still lacking. Furthermore, systemic or excessive iron chelation may disrupt host iron homeostasis, potentially leading to adverse reactions such as anemia, impaired cellular metabolism and compromised immune function. From a translational perspective, the clinical application of iron chelators in periodontitis faces several challenges. These include achieving localized drug delivery to periodontal tissues, minimizing systemic exposure, and establishing safe and efficacious dosing regimens. Consequently, while iron chelation represents a promising therapeutic strategy, further well-designed clinical investigations are required to evaluate its efficacy and safety in human subjects. The role of lactoferrin in periodontitis Lf, a member of the transferrin family, possesses the capacity to bind two ferric ions per molecule. Lf exerts diverse biological functions, including antimicrobial, anti-inflammatory and iron metabolism regulatory activities. Among various iron-related compounds, bovine lactoferrin (bLf) exhibits markedly higher translational potential, as it is classified by the FDA as a Generally Recognized as Safe (GRAS) substance [123]. Distinct from synthetic chelators that may lead to systemic iron depletion, bLf acts as an ‘intelligent regulator’. It can effectively sequester iron from pathogens while simultaneously preserving its bioavailability to support host tissue regeneration. Antimicrobial activity of lactoferrin Lf acts as an antibacterial agent by segregating iron. Compared to Tf, Lf retains iron ions at a lower pH and is able to play a greater role in acidic environments and sites of inflammation after infection [124]. The iron-dependent bactericidal function of Lf may be due not only to the removal of free iron ions but may involve Lf with the microbial cell surface. Lf disrupts the iron uptake system of bacteria by binding to the hemoglobin receptor (HbR) on the bacterial surface and removing it from the bacterial surface [125]. Moreover, Lf inhibits the activity of the cysteine proteases RgpA and Kgp and the formation of P. gingivalis biofilms [126]. In contrast, the direct interaction of Lf with the LPS of gram-negative bacteria or the lipoteichoic acid of gram-positive bacteria can exert iron-independent bactericidal effects [127]. Numerous studies have explored the incorporation of Lf as an additive for the treatment of oral diseases. A clinical trial demonstrated that the application of an Lf-supplemented gel resulted in a significantly greater reduction in PD and BOP compared with chlorhexidine gel [128]. Similarly, another clinical investigation evaluating Lf-based formulations against chlorhexidine and fluoride revealed that the Lf preparation exhibited superior antimicrobial efficacy, effectively reducing the pathogenic microbial load and inflammatory markers [129]. Beyond its antimicrobial properties, Lf plays a pivotal role in managing bone destruction. Local administration of a novel bLf peptide targeting the tumor necrosis factor receptor-associated factor 6 (TRAF6) binding site significantly decreased the number of osteoclasts in a rat model [130]. Furthermore, in the context of dental implant surgery, a single local dose of Lf solution enhanced the efficiency of autogenous bone grafting, promoting the healing of peri-implant defects and improving bone-to-implant contact in a rat femoral model [131]. Lactoferrin regulates iron homeostasis The complex mechanism of iron homeostasis has been further understood with the discovery of the FPN-hepcidin complex. Recent studies have shown that Lf also regulates iron homeostasis [132], mainly by modulating iron metabolism disorders during inflammation. LPS stimulation results in increased IL-6 and IL-1β cytokines, upregulated ferritin expression and downregulated FPN in macrophages, which were inhibited by bLf [133]. During infection and inflammation, iron homeostasis is severely disturbed, leading to AI. A clinical trial showed that oral administration of bLf before meals to pregnant women with inflammatory anemia resulted in significant increases in red blood cell, hemoglobin and total serum iron levels [134]. Another clinical study compared oral bLf and ferrous sulfate treatment in pregnant women with AI. bLf was more effective than ferrous sulfate in improving AI by reducing serum IL-6 and hepcidin levels [135]. Additionally, randomized controlled trials (RCTs) have demonstrated that the administration of lactoferrin to children with anemia secondary to chronic kidney disease (CKD) results in a significant increase in hemoglobin, erythrocyte counts and iron levels, outperforming the effects of iron dextran [136]. In summary, lactoferrin (Lf/bLf) modulates inflammatory cytokines and proteins involved in iron metabolism, thereby regulating iron homeostasis more effectively than conventional iron supplements. Challenges and limitations of targeting iron metabolism While modulating iron metabolism offers a novel therapeutic avenue, several important limitations must be considered. First, iron is essential for normal cellular function, and disrupting iron homeostasis may lead to unintended systemic effects, including anemia and impaired tissue repair. Second, the periodontal microenvironment is highly complex, involving interactions among host cells, the microbiota and immune responses, which may limit the effectiveness of single-target therapies. Third, heterogeneity among patients, including differences in disease severity, systemic health conditions and microbiome composition, may influence treatment outcomes. In addition, many current studies rely on simplified experimental models that do not fully replicate the clinical scenario. Finally, there is a lack of large-scale, well-controlled clinical trials, which limits the ability to draw definitive conclusions regarding the efficacy and safety of iron-targeting therapies. Future research should focus on bridging the gap between preclinical findings and clinical application. Key priorities include the development of targeted delivery systems to minimize systemic exposure, the identification of reliable biomarkers to guide patient selection and the design of RCTs to validate therapeutic efficacy. A more comprehensive understanding of the interplay between iron metabolism, host immunity and the oral microbiome will also be essential for optimizing these therapeutic strategies (Table 3). Table 3.Iron therapy as an anti-periodontitis treatment.CompoundEffectsMechanismEvidence levelReferencesMyricetinInhibition of bacterial growthIron-chelating activity;Inhibition of RgpA, RgpB and Kgp protease activitiesPreclinical (in vitro)[114]Tea polyphenolsInhibition of bacterial growthIron-chelating activity;Inhibition of hemolysisPreclinical (in vitro)[113]MRPInhibition of bacterial growthIron-chelating activityPreclinical (in vitro)[116]Bismuth drugsInhibition of bacterial growthDisruption of hemin and hemin-binding proteinsPreclinical (in vitro)[117]DeferoxamineInhibition of alveolar bone resorptionRegulation of Nrf2-mediated antioxidant pathways;Promotion of osteoblast differentiationPreclinical (in vitro)[119]Carnosic acidInhibition of ferroptosisactivating the Nrf2/GPX4 signaling axisPreclinical (in vitro and in vivo)[121]LactoferrinInhibition of bacterial growthIron binding activity;Lf binds HbR;Inhibition of rgpA and kgpPreclinical (in vitro)[125,126,137]LactoferrinInhibition of bacterial growth Clinical[128,129]LactoferrinPromotion of bone healing Preclinical (in vivo)[131]LactoferrinImproving anemiaIncreased Hb and serum ironClinical[136]Bovine lactoferrinInhibition of bone resorptionInhibition of TNF-α and RANKL expression upregulation;Osteoclast reductionPreclinical (in vitro and in vivo)[138]Bovine lactoferrinInhibition of bone resorptionInhibition of LPS-induced increase in TNF-α and IL-1βPreclinical (in vitro and in vivo)[130]Bovine lactoferrinRegulating iron homeostasis disorderIncreasing red blood cells, hemoglobin and serum ironClinical[134]Bovine lactoferrinTreatment of anemia of inflammationReducing IL-6 and increasing total serum ironClinical[135] Iron therapy as an anti-periodontitis treatment. Conclusions Iron is essential for oxygen transport, energy production, DNA synthesis and cellular respiration. Iron metabolism is tightly regulated in the body, and too high or too low levels of iron are harmful and can lead to many diseases. The maintenance of iron homeostasis involves the involvement of multiple molecules in the processes of iron uptake, iron storage and iron excretion, and the regulatory network of iron homeostasis is disrupted when the body is exposed to infection and inflammation. Periodontitis is a bacterial-mediated chronic inflammatory disease in which inflammation occurs with elevated levels of inflammatory cytokines and bacterial microorganisms and increased levels of ferritin and hepcidin expression, resulting in decreased serum iron and intracellular iron retention and leading to iron overload. Iron plays an important role in the pathological progression of periodontitis. Iron not only promotes microbial growth, causing inflammation and alveolar bone resorption, but also triggers cell death, especially ferroptosis. Moreover, changes in iron metabolism in periodontitis promote the development of systemic diseases, such as AI and diabetes mellitus. Besides, we summarize studies targeting iron metabolic therapies in periodontitis to regulate iron homeostasis and reduce tissue damage in periodontitis. Research on disorders of iron metabolism and ferroptosis in periodontitis is still in its early stages, and some issues need to be addressed: (1) more in-depth specific mechanisms of iron metabolism disorders in periodontitis; (2) specific changes in molecules involved in iron metabolism in patients with both systemic disease and periodontitis and (3) to determine the clinical effect of targeted iron therapy on controlling early inflammation and infection in periodontitis and promoting periodontal tissue regeneration. With further research, the relationships among iron metabolism, periodontitis and systemic diseases becomes clear. On this basis, anti-iron metabolism disorders can be considered as a target for the clinical treatment of periodontitis in the future. Even through the treatment of periodontitis, correcting iron metabolism disorders can improve systemic diseases.